Operating Income
West Pharmaceutical Services Operating Income increased by 13.1% to $177.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 65.5%, from $107.00M to $177.10M. Over 4 years (FY 2021 to FY 2025), Operating Income shows a downward trend with a -6.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
Higher operating income indicates strong operational efficiency and pricing power, while a decline suggests rising costs or weakening demand.
Detailed definition
Operating income is the profit realized from a company's core business operations after deducting all operating expenses...
Peer comparison
A standard benchmark for operational performance; peers are compared based on operating margin percentages.
operating_incomeHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $211.30M | $181.40M | $184.00M | $189.70M | $228.40M | $186.20M | $129.70M | $155.30M | $182.50M | $177.30M | $160.90M | $122.80M | $126.20M | $161.30M | $159.60M | $107.00M | $153.70M | $167.60M | $156.60M | $177.10M |
| QoQ Change | — | -14.2% | +1.4% | +3.1% | +20.4% | -18.5% | -30.3% | +19.7% | +17.5% | -2.8% | -9.2% | -23.7% | +2.8% | +27.8% | -1.1% | -33.0% | +43.6% | +9.0% | -6.6% | +13.1% |
| YoY Change | — | — | — | — | +8.1% | +2.6% | -29.5% | -18.1% | -20.1% | -4.8% | +24.1% | -20.9% | -30.8% | -9.0% | -0.8% | -12.9% | +21.8% | +3.9% | -1.9% | +65.5% |
Business Segments — Proprietary Products
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Proprietary Products | $131.00M | $158.20M | $162.30M | $130.60M | $161.70M | $175.20M | $189.70M | $189.20M |
| West Vantage | — | — | — | — | — | — | — | $15.60M |
| Contract-Manufactured Products | $17.20M | $21.80M | $16.20M | $13.50M | $17.80M | $22.30M | $9.80M | — |
| Total | $126.20M | $161.30M | $159.60M | $107.00M | $153.70M | $167.60M | $156.60M | $177.10M |
Contract-Manufactured Products was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Business Segments — Proprietary Products
| Segment | Q2 '21 | Q3 '21 | Q2 '22 | Q3 '22 |
|---|---|---|---|---|
| Proprietary Products | $216.20M | $195.50M | $233.90M | $188.60M |
| Contract-Manufactured Products | $18.70M | $16.80M | $14.20M | $14.70M |
| Total | $211.30M | $181.40M | $228.40M | $186.20M |
Contract-Manufactured Products, Proprietary Products were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
Operating Income at Other Companies
Frequently Asked Questions
- What is West Pharmaceutical Services's operating income?
- West Pharmaceutical Services (WST) reported operating income of $177.10M in Q1 2026.
- How has West Pharmaceutical Services's operating income changed year-over-year?
- West Pharmaceutical Services's operating income increased by 65.5% year-over-year, from $107.00M to $177.10M.
- What is the long-term trend for West Pharmaceutical Services's operating income?
- Over 4 years (2021 to 2025), West Pharmaceutical Services's operating income has grown at a -6.1% compound annual growth rate (CAGR), from $752.30M to $584.90M.
- What does operating income mean?
- The profit a company makes from its core business operations before interest and taxes.